Clinical Trial Update: Pharmacokinetic Assessment of Single-Dose Odanacatib (MK-0822) in Subjects With Severe Renal Insufficiency (MK-0822-067) [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetic assessment of a single dose of odanacatib (MK-0822) in subjects with severe renal insufficiency completed; results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Insufficiency

Drugs mentioned

• odanacatib (odanacatib)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Renal Insufficiency | Phase 1 | Status: COMPLETED | Results posted: 2018-02-26